



## **Avalanche Biotechnologies to Participate in Nomura's Biotechnology Conference**

October 30, 2014

MENLO PARK, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will participate in the "From Successful IPOs to Clinical Success: A Focus on New Crop of Companies Focused on Disorders of the Eye," panel discussion at Nomura's Biotechnology Conference on Thursday, November 6, 2014 at 10:00 am EST in Boston, MA.

### **About Avalanche Biotechnologies, Inc.**

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit [www.avalanchebiotech.com](http://www.avalanchebiotech.com).

#### **CONTACT: Investor Contact:**

Chris Erdman  
MacDougall Biomedical Communications  
(781) 235-3060  
[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)

#### **Media Contact:**

Kathy Vincent  
(310) 403-8951  
[kathy@kathyvincent.com](mailto:kathy@kathyvincent.com)

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.